AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RADIOPHARM THERANOSTICS LTD

0.023

+0.0014.55%

Volume:461.05K

Turnover:10.24K

Market Cap:81.52M

PE:-1.25

High:0.023

Open:0.023

Low:0.022

Close:0.022

52wk High:0.040

52wk Low:0.017

Shares:3.54B

Float Shares:2.86B

Volume Ratio:0.21

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-109.20%

ROA:-27.70%

PB:1.82

PE(LYR):-1.25

Loading ...

Overview Company News Filings

BRIEF-Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart

Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of Betabart (Rv-01)

THOMSON REUTERS

Radiopharm Theranostics Doses First Patient in Cancer Drug Candidate Phase 1/2a Clinical Trial; Shares Rise 5%

MT Newswires Live

Radiopharm Theranostics posts HY net cash outflows from operating activities of USD 22.67 million

Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates

Radiopharm Theranostics Slides As Insider Purchases Lose Another AU$25k

Simply Wall St.

Rad Increases Ownership in Radiopharm Ventures to 87.5%

THOMSON REUTERS

BRIEF-Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%

Radiopharm Theranostics - Co Increases Ownership in Radiopharm Ventures to 87.5%

THOMSON REUTERS

Radiopharm Theranostics - Secures at the Market Equity Facility for up to US$22.4 Mln

THOMSON REUTERS

BRIEF-Radiopharm Theranostics Ltd May Offer & Sell Up To $50 Million From Time To Time In One Or More Offerings- SEC Filing

Radiopharm Theranostics Ltd May Offer & Sell up to $50 Mln From Time to Time in One or More Offerings- SEC Filing

THOMSON REUTERS

Radiopharm Theranostics Ltd: Achieves Primary Endpoint in 92% of Patients at Interim Analysis of Rad 101 Phase 2B Imaging Trial in Brain Metastases

THOMSON REUTERS

Radiopharm Theranostics Reports 92% Success Rate for RAD 101 in Phase 2b Brain Metastases Trial

Radiopharm Theranostics Held General Meeting

Radiopharm Theranostics Appoints Bruce Goodwin as Director

Radiopharm Theranostics Ltd-Life Sciences Leader Bruce Goodwin Appointed to Board

THOMSON REUTERS

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of Rad 402 (Klk3-Mab With Tb161) in Advanced Prostate Cancer

THOMSON REUTERS

ASX Midday Sector Update: Information Technology Leads Selloff; Healthcare Bucks Downward Trend

MT Newswires Live

Radiopharm Theranostics Receives Ethics Committee Nod for Prostate Cancer Treatment Trial; Shares Down 4%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RAD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.023,"timestamp":1771988604332,"preClose":0.022,"halted":0,"volume":461049,"delay":0,"changeRate":0.0454545454545455,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":2856071021,"shares":3544216000,"eps":-0.018424,"marketStatus":"Trading","change":0.001,"latestTime":"02-25 14:13:54 AEDT","open":0.023,"high":0.023,"low":0.022,"amount":10244,"amplitude":0.045455,"askPrice":0.023,"askSize":2273148,"bidPrice":0.022,"bidSize":1988345,"shortable":3,"etf":0,"ttmEps":-0.018424,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771995600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.022,"openAndCloseTimeList":[[1771974000000,1771995600000]],"volumeRatio":0.206437,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":2856071021,"roa":"-27.70%","roe":"-109.20%","lyrEps":-0.018424,"volumeRatio":0.206437,"shares":3544216000,"dividePrice":0,"high":0.023,"amplitude":0.045455,"preClose":0.022,"low":0.022,"week52Low":0.017,"pbRate":"1.82","psRate":"6.52","week52High":0.04,"institutionHeld":0,"latestPrice":0.023,"committee":-0.066832,"eps":-0.018424,"divideRate":0,"volume":461049,"delay":0,"ttmEps":-0.018424,"open":0.023,"prevYearClose":0.025,"prevWeekClose":0.022,"prevMonthClose":0.021,"prevQuarterClose":0.025,"fiveDayClose":0.022,"twentyDayClose":0.023,"sixtyDayClose":0.022,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613711486","title":"BRIEF-Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711486","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613711486?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:02","pubTimestamp":1771938144,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of BetabartFeb 24 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:RADIOPHARM THERANOSTICS DOSES FIRST PATIENT IN PHASE 1/2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA7KDRYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2613167057","title":"Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of Betabart (Rv-01)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613167057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613167057?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:30","pubTimestamp":1771936201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA7KDRYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2613575687","title":"Radiopharm Theranostics Doses First Patient in Cancer Drug Candidate Phase 1/2a Clinical Trial; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613575687","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613575687?lang=en_us&edition=fundamental","pubTime":"2026-02-24 10:02","pubTimestamp":1771898575,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics (ASX:RAD) said the first patient was dosed in its first-in-human phase 1/2a dose escalation and expansion clinical trial of lutetium-177-Betabart drug candidate, or RV-01, for ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2606158327","title":"Radiopharm Theranostics posts HY net cash outflows from operating activities of USD 22.67 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2606158327","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606158327?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:00","pubTimestamp":1769601655,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. reported its financial results for the first half of fiscal 2026 ended December 31, 2025. The company recorded net cash outflows from operating activities of USD 22.67 million during the period. Cash and cash equivalents stood at USD 34.52 million, providing a runway into 2027 to support the advancement of its radiotherapeutic pipeline through key clinical and regulatory milestones. In October 2025, Radiopharm Theranostics secured commitments to raise approximately USD 35 million via private placement from international and Australian institutional and industry investors. Payments to related parties during the half-year period encompassed remuneration for director fees to executive and non-executive directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL4XCG9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK7067","SG9999014021.USD","LU2095319765.USD","SG9999014039.USD","BK4112","RAD.AU","LU0314104364.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2606715341","title":"Press Release: Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2606715341","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606715341?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:00","pubTimestamp":1769601600,"startTime":"0","endTime":"0","summary":"Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases. Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026. Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regulatory milestones. RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of the molecule in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins. RAD 101 has received U.S. Food and Drug Administration  Fast Track Designation to expedite the review process and help bring the novel imaging small molecule to the over 300,000 patients diagnosed annually in the U.S. with cerebral metastases. The study is cur","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009354923.USD","BK4183","RAD.AU","BK4213","DSMC","BK7067","SOC","ODD"],"gpt_icon":0},{"id":"2605257444","title":"Radiopharm Theranostics Slides As Insider Purchases Lose Another AU$25k","url":"https://stock-news.laohu8.com/highlight/detail?id=2605257444","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605257444?lang=en_us&edition=fundamental","pubTime":"2026-01-23 07:39","pubTimestamp":1769125188,"startTime":"0","endTime":"0","summary":"The recent 12% drop in Radiopharm Theranostics Limited's ( ASX:RAD ) stock could come as a blow to insiders who...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/radiopharm-theranostics-slides-as-insider-purchases-lose-ano","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rad/radiopharm-theranostics-shares/news/radiopharm-theranostics-slides-as-insider-purchases-lose-ano","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2602140385","title":"Rad Increases Ownership in Radiopharm Ventures to 87.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602140385","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602140385?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:08","pubTimestamp":1768219689,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YD15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2602569918","title":"BRIEF-Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602569918","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602569918?lang=en_us&edition=fundamental","pubTime":"2026-01-12 09:14","pubTimestamp":1768180454,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%Jan 12 (Reuters) - Radiopharm Theranostics Ltd RAD.AX:CO INCREASES OWNERSHIP IN RADIOPHARM VENTURES TO 87.5%Further company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nFWN3YA1N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2602676568","title":"Radiopharm Theranostics - Co Increases Ownership in Radiopharm Ventures to 87.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602676568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602676568?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:28","pubTimestamp":1768166928,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nFWN3YA1N9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2592492644","title":"Radiopharm Theranostics - Secures at the Market Equity Facility for up to US$22.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2592492644","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592492644?lang=en_us&edition=fundamental","pubTime":"2025-12-18 11:43","pubTimestamp":1766029424,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XN1C8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2592495847","title":"BRIEF-Radiopharm Theranostics Ltd May Offer & Sell Up To $50 Million From Time To Time In One Or More Offerings- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592495847","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592495847?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:22","pubTimestamp":1765923773,"startTime":"0","endTime":"0","summary":"BRIEF-Radiopharm Theranostics Ltd May Offer & Sell Up To $50 Million From Time To Time In One Or More Offerings- SEC FilingDec 16  - Radiopharm Theranostics Ltd RAD.AX:RADIOPHARM THERANOSTICS LTD MAY OFFER & SELL UP TO $50 MILLION FROM TIME TO TIME IN ONE OR MORE OFFERINGS- SEC FILINGSource text: [ID:n0001213900-25-122349]Further company coverage: RAD.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM0XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"gpt_icon":1},{"id":"2592586479","title":"Radiopharm Theranostics Ltd May Offer & Sell up to $50 Mln From Time to Time in One or More Offerings- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592586479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592586479?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:13","pubTimestamp":1765923223,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nFWN3XM0XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2591180645","title":"Radiopharm Theranostics Ltd: Achieves Primary Endpoint in 92% of Patients at Interim Analysis of Rad 101 Phase 2B Imaging Trial in Brain Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2591180645","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591180645?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:06","pubTimestamp":1765800406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL024:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2591645304","title":"Radiopharm Theranostics Reports 92% Success Rate for RAD 101 in Phase 2b Brain Metastases Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591645304","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591645304?lang=en_us&edition=fundamental","pubTime":"2025-12-15 20:00","pubTimestamp":1765800048,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. announced interim results from its U.S. Phase 2b clinical imaging trial of RAD 101 in patients with brain metastases. According to the company, 92% of evaluable patients  achieved concordance with MRI imaging, meeting the primary endpoint of the study. RAD 101, a novel small-molecule imaging agent targeting fatty acid synthase  and radiolabelled with Fluorine-18, demonstrated significant and selective tumor uptake in suspected or recurrent brain metastases. The interim data have been presented by the company, and a webinar is scheduled to discuss the findings. Radiopharm Theranostics also indicated plans to initiate a pivotal study by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiophar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3GjGv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","BK4585","BK7067","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2588488566","title":"Radiopharm Theranostics Held General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588488566","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588488566?lang=en_us&edition=fundamental","pubTime":"2025-12-04 19:03","pubTimestamp":1764846209,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. held a general meeting on December 3, 2025. Shareholders approved the ratification of the prior issue of First Tranche Placement Shares to placement participants. Approval was also granted for the issue of Second Tranche Placement Shares, the issue of Placement Attaching Options, and the issue of SPP Attaching Options. All proposals put forward at the meeting were carried.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL1WPyy8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2584949766","title":"Radiopharm Theranostics Appoints Bruce Goodwin as Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949766","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949766?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557238,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd. has announced the appointment of Bruce Goodwin as a new director, effective 19 November 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL9ggSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2584499367","title":"Radiopharm Theranostics Ltd-Life Sciences Leader Bruce Goodwin Appointed to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2584499367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584499367?lang=en_us&edition=fundamental","pubTime":"2025-11-19 09:43","pubTimestamp":1763516610,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUEBJNRS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAD.AU","BK7067"],"gpt_icon":0},{"id":"2584939961","title":"Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of Rad 402 (Klk3-Mab With Tb161) in Advanced Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584939961","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584939961?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:08","pubTimestamp":1763464129,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","RAD.AU"],"gpt_icon":0},{"id":"2584047536","title":"ASX Midday Sector Update: Information Technology Leads Selloff; Healthcare Bucks Downward Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=2584047536","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584047536?lang=en_us&edition=fundamental","pubTime":"2025-11-18 10:45","pubTimestamp":1763433918,"startTime":"0","endTime":"0","summary":"The healthcare sector was the only one in the green, gaining just 0.2% at midday Tuesday, after the S&P/ASX 200 index fell 131.30 points, or 1.5%, to 8,505.10, to the lowest point in five months.Minutes from the Reserve Bank of Australia's November meeting showed that the increase in inflation in the September quarter was larger than expected, and its monetary policy board affirmed that it was appropriate in this environment for its decisions to \"remain cautious and data dependent.\"Radiopharm Theranostics  received approval from the Bellberry Human Research Ethics Committee in Australia to start its first-in-human phase 1 clinical trial of RAD 402 for the potential treatment of prostate cancer.The information technology sector plummeted nearly 6%. The Nasdaq composite and S&P 500 indices fell nearly 1% on Wall Street, while the Dow Jones declined over 1%.Technology One , which fell over 16%, reported that its earnings per share in fiscal 2025 rose to AU$0.4173 from AU$0.3603 a year ear","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4137","XJO.AU","BK7067","III","LU0029874061.USD","XKO.AU","BK4134","XAO.AU","BK4588","BK4581","HCSG","XBI","RAD.AU","BK7503","TNE.AU","BK4585","BK7016","XLV","LU0128526141.USD","LABU"],"gpt_icon":0},{"id":"2584018846","title":"Radiopharm Theranostics Receives Ethics Committee Nod for Prostate Cancer Treatment Trial; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584018846","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584018846?lang=en_us&edition=fundamental","pubTime":"2025-11-18 09:49","pubTimestamp":1763430582,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics  received approval from the Bellberry Human Research Ethics Committee in Australia to start its first-in-human phase 1 clinical trial of RAD 402 for the potential treatment of prostate cancer, according to a Tuesday filing with the Australian bourse.Shares of the company fell past 4% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAD.AU","XKO.AU","XJO.AU","BK7067","XAO.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":52,"code":"91000000","status":"200"}]}}